Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Ms related abstracts ens june 2013 barcelona

1,968 views

Published on

Published in: Health & Medicine
  • Be the first to comment

Ms related abstracts ens june 2013 barcelona

  1. 1. Search resultSearch Result: Session ChairSATURDAY, JUNE 08, 2013SUNDAY, JUNE 09, 2013MONDAY, JUNE 10, 2013TUESDAY, JUNE 11, 2013Search Result: AbstractsSATURDAY, JUNE 08, 201311:55 - 12:15 / TEVA PHARMACEUTICALS EUROPE BV SATELLITE SYMPOSIUM : EMERGING INSIGHTS IN MULTIPLE SCLEROSIS: RE-EVALUATING THE TREATMENT ALGORITHM / ROOM A13:30 - 14:15 / TEACHING COURSE 5 : LONGITUDINAL MONITORING WITH NEUROIMAGING TECHNIQUES / ROOM EPersonal programme DisplayPrint current view print11:50 - 13:20Teva Pharmaceuticals Europe BV Satellite Symposium: Emerging insights in Multiple Sclerosis: re-evaluating the treatment algorithmRoom AA. Rovira (Barcelona, ES)P. Rieckmann (Bamberg, DE)11:30 - 12:30Poster Session 1: Multiple Sclerosis: clinical aspects IPoster AreaK. Fink (Stockholm, SE)13:45 - 15:15Oral Session 2: Multiple Sclerosis I: TherapeuticsRoom DX. Montalban (Barcelona, ES)L. Kappos (Basel, CH)15:45 - 17:15Joint ENS-SEN Symposium: Role of antibodies in Multiple SclerosisRoom DO. Fernandez (Malaga, ES)P. Soelberg Sørensen (Copenhagen, DK)11:30 - 12:30Poster Session 2: Multiple Sclerosis: clinical aspects IIPoster AreaH.-P. Hartung (Düsseldorf, DE)13:30 - 15:00Oral Session 13: Multiple Sclerosis II: pathology and pathogenesisRoom AG. Comi (Milan, IT)O. Ciccarelli (London, GB)15:30 - 17:00Oral Session 18: Multiple Sclerosis III: OtherRoom AI. Milonas (Athens, GR)H.-P. Hartung (Düsseldorf, DE)17:30 - 18:30Poster Session 3: Multiple Sclerosis: clinical aspects IIIPoster AreaJ. Sastre-Garriga (Barcelona, ES)09:00 - 11:00Symposium: Personalised treatment in Multiple SclerosisPlenary HallG. Comi (Milan, IT)11:30 - 12:30Poster Session 4: Multiple Sclerosis: pathology and pathogenesisPoster AreaO. Fernández (Malaga, ES)13:30 - 17:00Teaching Course 17: Measuring heterogeneity in Multiple Sclerosis: the MRI perspectiveRoom AM. Filippi (Milan, IT)J. Geurts (Amsterdam, NL)Multiple Sclerosis: Changing concepts, new targetsF. Barkhof (Amsterdam, NL)
  2. 2. 18:15 - 18:45 / PRESIDENTIAL SYMPOSIUM : SLEEP FOR THE BRAIN, BY THE BRAIN / PLENARY HALL18:45 - 19:15 / PRESIDENTIAL SYMPOSIUM : SLEEP FOR THE BRAIN, BY THE BRAIN / PLENARY HALLSUNDAY, JUNE 09, 201311:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : NEUROIMAGING / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : NEUROREHABILITATION / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREAMultiple SclerosisF. Fazekas (Graz, AT)Sleep-wake disorders as first/main manifestation of a neurological disorderJ. Santamaria (Barcelona, ES)Sleep-wake disorders as modulators of the outcome of neurological disordersC.L. Bassetti (Berne, CH)Relationship between early disease activity and long-term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years inrelapsing-remitting multiple sclerosisH.-P. Hartung, F. Barkhof, G. Comi, L. Kappos, B. Khatri, X. Montalban, J. Pelletier, E.Kornyeyeva, D. Piani Meier, S. Ritter, P. von Rosenstiel, D. Tomic, J. Cohen (Düsseldorf, DE;Amsterdam, NL; Milan, IT; Basel, CH; Milw aukee, US; Barcelona, ES; Marseille, FR; EastHanover, US; Cleveland, US)Functional and structural disruption of the precuneus contributes to cognitive impairment in paediatric multiple sclerosisM. Filippi, M. Absinta, M.P. Amato, A. Ghezzi, L. Moiola, A. Fiorino, P. Veggiotti, G. Comi, M.A.Rocca and the MS and Neuroimaging Study Groups of the Italian Neurological SocietySustainable effects of a 12-week patient education programme in multiple sclerosis patients: a qualitative analysisS. Kersten, J. Drosselmeyer, C.T. Haas (Saarbrücken, Idstein, DE)Association of improvement in fatigue with improvement in depression and sleepiness in natalizumab-treated multiple sclerosis (MS) patients: results fromthe TYNERGY studyI.-K. Penner, E.G. Celius, S. Fuchs, K. Schreiber, S. Berkö, J. Sun, E. Falk, A. Svenningsson(Basel, CH; Oslo, NO; Graz, AT; Copenhagen, DK; Upplands Väsby, SE; Weston, US; Umeå,SE)Clinical and instrumental predictors of efficacy of natalizumab therapy in the course of multiple sclerosis: a retrospective study from a single centreV. Lo Re, G. Salemi, P. Ragonese, M. Lo Re, M.A. Mazzola, S. Realmuto, G. Savettieri (Palermo,IT)Natalizumab saturation: potential biomarker for individual duration of treatment holiday after natalizumab withdrawalP. Wipfler, A. Harrer, G. Pilz, K. Oppermann, S. Afazel, E. Haschke-Becher, E. Trinka, J. Kraus(Salzburg, AT)Adherence to, and effectiveness of, treatment with subcutaneous interferon beta-1a in relapsing multiple sclerosis patients using RebiSmart™ for self-injection: one-year interim results of an international, prospective, observational studyA. Bayas, J.-C. Ouallet, B. Kallmann, U. Fulda, K. Marhardt (Augsburg, DE; Bordeaux, FR;Bamberg, Darmstadt, DE; Geneva, CH)Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoringR. Alroughani, H. Aref, S. Bohlega, I. Al Sherooqi, M. Dahdaleh, I. Feki, M. Jumah, M. Al-Kaw i,S. Koussa, M. Sahraian, B. Yamout (Kuw ait, KW; Cairo, EG; Riyadh, SA; Manama, BH; Amman,JO; Sfax, TN; Beirut, LB; Tehran, IR)
  3. 3. 11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : INFLAMMATORY AND MYASTHENIA / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : PRECLINICAL NEUROBIOLOGY / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : NEUROOPHTHALMOLOGY AND BALANCE / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREAHealth-related quality of life over time of patients with multiple sclerosis treated with interferon beta-1a: the COMPARE studyB.G. Vickrey, L. Lee, F. Moore, K. Fortin (Los Angeles, US; Toronto, CA; Montréal, US;Montréal, CA)Comparable efficacy of immunomodulatory treatment of relapsing-remitting multiple sclerosis (RRMS) in daily practice: the ASSET (AVONEX assessment inmultiple sclerosis therapy) study, an observational study in 1343 patientsM. Marziniak, K. Taipale, K. Rehberg-Weber, C. Wernsdörfer on behalf of the ASSET studygroupSuccessful desensitization in a patient with hypersensitivity reaction to natalizumab: a case reportM. Bouktsi, A. Manikas, M. Zande, I. Milonas (Thessaloniki, GR)Natalizumab rechallenge in multiple sclerosis patients: postponing the unavoidable?L. Ferrè, F. Sangalli, L. Moiola, M. Radaelli, V. Barcella, M. Rodegher, B. Colombo, V. Martinelli,G. Comi (Milan, IT)Abnormally severe immune reconstitution inflammatory syndrome (IRIS) in a multiple sclerosis (MS) patient with natalizumab-associated progressivemultifocal leukoencephalopathy (PML)A. Calvi, M. De Riz, A.M. Pietroboni, L. Ghezzi, A. Arighi, G.G. Fumagalli, V. Maltese, G. Comi,D. Galimberti, E. Scarpini (Milan, IT)Persistence, adherence, quality of life, and treatment satisfaction in patients treated with the AVONEX® PEN^TM: an interim analysis of PERSISTB. Sperling, S. Slaw ka, C. Ghaus, X. You on behalf of the PERSIST Study GroupAssociations between baseline factors and on-treatment relapses in natalizumab-treated patients with relapsing-remitting multiple sclerosis in theTYSABRI® (natalizumab) observational programmeH. Wiendl, H. Butzkueven, L. Kappos, F. Pellegrini, M. Trojano, A. Zhang, S. Belachew(Münster, DE; Victoria, AU; Basel, CH; Chieti, Bari, IT; Weston, US)A prospective, open-label, single-arm clinical trial of the effects of natalizumab on measures of ambulation in relapsing-remitting multiple sclerosispatients: the TIMER studyN. Voloshyna, T. Nechrych, X. You, S. Belachew , D. Paes (Kharkiv, Lviv, UA; Weston, US)Clinical and neuroradiological evaluation in neurosarcoidosisG. Gözbatik-Celik, U. Uygunoglu, D. Uluduz, S.N. Yeni, S. Saip, A. Siva (Istanbul, TR)Intrathecal transplantation of neural stem/precursor cells derived from induced pluripotent stem cells improves the clinical and neuropathological outcomeof a mouse model of multiple sclerosisC. Laterza, A. Merlini, D. De Feo, F. Ruffini, E. Brambilla, A. Lombardo, M. Onorati, E. Cattaneo,G. Comi, G. Martino (Milan, IT)A preliminary longitudinal study of the retinal nerve fibre layer in clinically isolated syndromes (CIS)C. Oreja-Guevara, S. Noval, A. Royo, B. Chamorro, J. Alvarez-Linera (Madrid, ES)Clinical management of high-risk patients with relapsing-remitting multiple sclerosis (MS) treated with natalizumab
  4. 4. 11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : NEUROIMAGING / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : INFLAMMATORY AND MYASTHENIA / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREAK.H. Vo, L. Stazzone, N. Drago, H. Nguyen, G. Buckle (Boston, Brookline, US)Follow-up of multiple sclerosis (MS) patients after natalizumab interruption. Clinical and MRI findings. Switching to treatment with fingolimodM.E. Evangelopoulos, E. Andreadou, C. Deligianni, G. Saltogiannis, I. Chasalevris, V. Chaina, C.Kilidireas (Athens, GR)Seroconversion rates to JC virus (JCV) in multiple sclerosis patients is higher than previously reportedG. Izquierdo, M. Rus, M.D. Paramo, J.L. Peña, L. Dinca, S. Perez, G. Navarro, M. Lucas (Seville,ES)Patient and nurse assessment of the ExtaviJect® 30Gdevice for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospectiveEuropean studyG. Boeru, I. Milanov, K. Kmetska, F. De Robertis, S. Rojas-Farreras, A. Kulla, M. Tomlinson(Bucharest, RO; Sofia, BG; Lecce, IT; Barcelona, ES; Basel, CH)Patient adherence to subcutaneous interferon beta-1a delivered via the electronic self-injection device RebiSmart: an observational, retrospective study inthe United Kingdom and IrelandL. Parkes, K. Marhardt, H. Willis, A.M. Larkin (Feltham, GB; Geneva, CH; Chelmsford, GB;Dublin, IE)Natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients: survival and functional outcome when asymptomatic atdiagnosisT. Dong-Si, S. Richman, G. Bloomgren, M. Wenten, J. Philip, S. Datta, J. McIninch, C. Bozic, B.Ticho, N. Richert (Weston, US)Improvement in quality of life outcomes with prolonged-release fampridine treatment: six month interim analysis of the ENABLE studyR. Macdonell, G. Nagels, P.S. Sorensen, D. Laplaud, C. Pozzilli, B. de Jong, A.M. Silva, R.Nicholas, M. Niedhammer, J. Gaebler, S. Agarw al, J. Potts (Heidelberg, AU; Melsbroek, BE;Copenhagen, DK; Nantes, FR; Rome, IT; Nijmegen, NL; Porto, PT; London, GB; Oldenburg, DE;Weston, US)Retinal nerve fibre layer and brain atrophy in relapsing-remitting multiple sclerosis: a longitudinal correlation studyA. Bisecco, A. Gallo, M. Lanza, R. Sacco, S. Borrelli, L. Lavorgna, M. Cirillo, S. Bonavita, F.Esposito, G. Tedeschi (Naples, IT)Natalizumab is effective in patients with active relapsing-remitting multiple sclerosis: a Middle Eastern experienceR. Alroughani, J. Al Hashel, S. Ahmed, A. Thussu (Kuw ait, KW)MTCH1 antibodies in neuromyelitis optica patients with or without aquaporin-4 antibodiesA. Çoban, F. Çavus, C. Ulusoy, S. Turan, B. Vural, R. Türkoglu, M. Kürtüncü, M. Eraksoy, G.Akman-Demir, E. Tüzün (Istanbul, TR)An integrated analysis of safety and tolerability of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from phase 2 and 3placebo-controlled studiesJ.T. Phillips, R.J. Fox, R. Gold, E. Havrdova, L. Kappos, K. Raghupathi, H. Yuan, V. Viglietta, S.I.Sheikh, K.T. Daw son, M. Novas, M.T. Sw eetser, K. Selmaj (Dallas, Cleveland, US; Bochum, DE;Prague, CZ; Basel, CH; Weston, US; Lodz, PL)An integrated analysis of the clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINEand CONFIRM studies
  5. 5. 11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA13:45 - 14:00 / ORAL SESSION 2 : MULTIPLE SCLEROSIS I: THERAPEUTICS / ROOM D14:00 - 14:15 / ORAL SESSION 3 : NEUROPHYSIOLOGY / ROOM E14:00 - 14:15 / ORAL SESSION 2 : MULTIPLE SCLEROSIS I: THERAPEUTICS / ROOM D14:15 - 14:30 / ORAL SESSION 2 : MULTIPLE SCLEROSIS I: THERAPEUTICS / ROOM D14:30 - 14:45 / ORAL SESSION 2 : MULTIPLE SCLEROSIS I: THERAPEUTICS / ROOM D14:45 - 15:00 / ORAL SESSION 2 : MULTIPLE SCLEROSIS I: THERAPEUTICS / ROOM D15:00 - 15:15 / ORAL SESSION 2 : MULTIPLE SCLEROSIS I: THERAPEUTICS / ROOM D17:00 - 17:15 / ORAL SESSION 7 : NEURO-ONCOLOGY AND MISCELLANEOUS / ROOM EMONDAY, JUNE 10, 201309:45 - 10:00 / ORAL SESSION 10 : NEUROIMAGING / ROOM CR.J. Fox, D.H. Miller, J.T. Phillips, D.L. Arnold, K. Selmaj, M. Yang, R. Zhang, K.T. Daw son, V.Viglietta, S.I. Sheikh, R. Gold (Cleveland, US; London, GB; Dallas, US; Montreal, CA; Lodz, PL;Weston, US; Bochum, DE)Safety, tolerability and patient evaluation of peginterferon beta-1a administered via a single-use autoinjector in relapsing multiple sclerosis: data from thePhase 3b ATTAIN sub-studyS. Hung, A. Deykin, A. Seddighzadeh, S. Liu, B. Sperling, P. Calabresi (Cambridge, Baltimore,US)Immunomodulatory effects of a new CB2-selective cannabinoid agonist on T-cells from multiple sclerosis patientsP. Annunziata, C. Cioni, L. De Santi, C. Mugnaini, S. Pasquini, F. Corelli (Siena, IT)Clinical efficacy and safety of peginterferon beta-1a in relapsing multiple sclerosis: data from the pivotal phase 3 ADVANCE studyB. Kieseier, D.L. Arnold, L. Balcer, A. Boyko, J. Pelletier, A. Deykin, S. Hung, A. Seddighzadeh,S. Liu, Y. Zhu, B. Sperling, P. Calabresi (Düsseldorf, DE; Montreal, CA; Philadelphia, US;Moscow , RU; Marseille, FR; Cambridge, Baltimore, US)Evoked potentials predict disease-modifying treatment response in multiple sclerosisL. Leocani, M. Bianco, G. Di Maggio, S. Medaglini, J. Gonzalez-Rosa, R. Chieffo, U. Del Carro,L. Moiola, V. Martinelli, G. Comi (Milan, IT)Use of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosisT. Plavina, M. Subramanyam, G. Bloomgren, S. Richman, A. Pace, S. Lee, B. Schlain, D.Campagnolo, B. Ticho (Weston, US)An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiplesclerosis from the phase 3 DEFINE and CONFIRM studiesA. Bar-Or, R.J. Fox, R. Gold, D.H. Miller, D.L. Arnold, J. OGorman, M. Yang, S.I. Sheikh, V.Viglietta, K.T. Daw son, M. Hutchinson (Montreal, CA; Cleveland, US; Bochum, DE; London, GB;Weston, US; Dublin, IE)Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS IIO. Fernandez, D.L. Arnold, J.A. Cohen, A.J. Coles, C. Confavreux, E.J. Fox, H.-P. Hartung, E.Havrdova, K. Selmaj, H. Weiner, C.L. Tw yman, T. Miller, S.L. Lake, D.H. Margolin, M.A. Panzara,D.A.S. Compston for the CARE-MS II InvestigatorsCatastrophic multiple sclerosis rebound after natalizumab treatment discontinuationC. Tur, M. Tintoré, Á. Vidal-Jordana, J. Rio, A.C. Wing, B. Canneti, M. Torres, M.J. Arevalo, J.Castillo, I. Galan, R. Horno, M.J. Vicente, M.I. Martin, M. Comabella, À. Rovira, J. Sastre-Garriga,X. Montalban (Barcelona, ES)Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis: exploratory analysis of 15-year data from the PRISMS studyL. Kappos, B. Uitdehaag, J. Kuhle, D. Issard, F. Casset-Semanaz (Basel, CH; Amsterdam, NL;Geneva, CH)Professionals’ opinions on the physical factors affecting quality of life in multiple sclerosis and motor neurone disease: pilot work from the Trajectories ofOutcomes in Neurological Conditions studyB. OSullivan, N. Rose, J. Griffiths, C.A. Young on behalf of the Trajectories of Outcome inNeurological Conditions (TONiC) Study GroupHigh resolution magnetization transfer imaging to study the specific contribution of white matter and grey matter to disability in multiple sclerosis
  6. 6. 10:00 - 10:15 / ORAL SESSION 10 : NEUROIMAGING / ROOM C10:45 - 11:00 / ORAL SESSION 10 : NEUROIMAGING / ROOM C11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : DEMENTIA I: TREATMENT AND BIOMARKER / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREAA. Papadopoulou, M. Amann, M. Andelova, N. Müller-Lenke, Y. Naegelin, C. Stippich, E.W.Radue, O. Bieri, L. Kappos, T. Sprenger (Basel, CH)Abnormalities of the brain connectome in patients with multiple sclerosisM. Filippi, P. Valsasina, S. Sala, A. Meani, A. Falini, G. Comi, M.A. Rocca (Milan, IT)Structural correlates of abnormalities of cervical cord functional MRI activity in patients with multiple sclerosisM.A. Rocca, P. Valsasina, M. Copetti, D. Caputo, M. Absinta, M. Filippi (Milan, San GiovanniRotondo, IT)Safety and cardiac outcomes of fingolimod 0.5 mg in the Italian cohort from the 4-month, open-label, single-arm, multi-centre FIRST studyG. Marrosu, G. Comi, S. Ruggieri, A. Francia, S. Cottone, D. Maimone, R. Turrini, A. Sinha, P.Von Rosenstiel, D. Tomic (Cagliari, Milan, Pozzilli, Rome, Palermo, Catania, Orrigio, IT;Hyderabad, IN; Basel, CH)Autologous mesenchymal stem cell transplantation in multiple sclerosisY. Motuzova, M. Zafranskaya, D. Nizheharodova, A. Borisov, I. Svirid, D. Balvanovich, T.Kachan, M. Minzer, E. Selezneva, A. Fedulov (Minsk, BY)Impact of a single relapse in disability and progression in multiple sclerosis: a random forest approachL.A. Rodríguez de Antonio, I. Pulido-Valdeolivas, D. Gómez-Andrés, M.J. Aguilar-Amat, A.Cruz-Herranz, I. González-Suárez, A. Tallón-Barranco, E. Díez-Tejedor (Madrid, ES)Fixed-dose dextromethorphan and quinidine is effective in the treatment of pseudobulbar affect due to neurodegenerative conditions: a case seriesD. Kantor (Ponte Vedra, US)Overall safety and relapse outcomes in fingolimod-treated patients previously exposed to natalizumab in the 4-month, open label FIRST studyG. Comi, R. Gold, F. Dahlke, A. Sinha, P. Von Rosenstiel, D. Tomic, L. Kappos (Milan, IT;Bochum, DE; Basel, CH; Hyderabad, IN)Optical coherence tomography (OCT) study in multiple sclerosis patients treated with fingolimodC. Oreja-Guevara, M. Capote Díez, B. Chamorro Hernández, S. Noval Martin (Madrid, ES)Safety and efficacy of intravenous injection of autologous bone marrow-derived mesenchymal stem cell in patients with multiple sclerosis: a double blindrandomized semi-crossover clinical trial: preliminary report 1 - safety issuesS.M. Nabavi, N. Aghdami, L. Arab, A. Hamzeloo (Tehran, IR)Long-term effects of cognitive rehabilitation in multiple sclerosis: 12-month follow-upA. Altinkaya, I. Guclu, E. Kurt, A. Bingöl, A. Soysal, D. Yandim Kuscu, D. Kirbas, B. Topcular(Istanbul, TR)Early mobility impairment: bridging the communication gap between people with multiple sclerosis and their healthcare providersB. Anderseck, P. Van Asch, J. Johnson, S. Agarw al, S. Hudgens, L. Humphrey, R. Medcalf, T.Ziemssen (Valens, CH; Kontich, BE; Weston, MA, Weston, Boston, US; Cheshire, GB;
  7. 7. 11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : CEREBROVASCULAR DISORDERS: SEMIOLOGY AND CASE REPORTS / POSTER AREADresden, DE)Cardiac effects of fingolimod in patients with multiple sclerosisB.L. Hughes, M. Cascione, K. McCague, L. Pestreich, L. Schofield, E. Kim, L.M. Barbato (DesMoines, Tampa, East Hanover, US)Alemtuzumab improves quality of life compared to SC IFNB-1a in CARE-MS IIR. Arroyo, D.L. Arnold, J.A. Cohen, A.J. Coles, C. Confavreux, E.J. Fox, H.-P. Hartung, E.Havrdova, K. Selmaj, H. Weiner, C.L Tw yman, T. Miller, A. Boscoe, S.L Lake, D.H. Margolin, M.Panzara, D.A.S. Compston for the CARE-MS II InvestigatorsNo effect on incidence of infection after therapy switch to fingolimodC. LaGanke, D.R. Wynn, K. McCague, L.M. Barbato, R. Hashmonay (Cullman, Northbrook, EastHanover, US)Teriflunomide hepatic safety results: pooled data from three placebo-controlled studiesC. Confavreux, T.P. Olsson, G. Comi, M.S. Freedman, A. Miller, J.S. Wolinsky, L. Kappos, J.-L.Delhay, H. Li, P. Truffinet, P. O’Connor (Lyon, FR; Stockholm, SE; Milan, IT; Ottaw a, CA; NewYork, Houston, US; Basel, CH; Chilly Mazarin, FR; Bridgew ater, US; Toronto, US)Exploring the impact of teriflunomide on immune cells in patients with relapsing multiple sclerosis: design of the Teri-Dynamic studyF. Menguy-Vacheron, R. Varona, A. Posevitz-Fejfar, V. Posevitz, L. Klotz, H. Wiendl (ChillyMazarin, FR; Münster, DE)Improved quality of life after therapy change to fingolimodH. Crayton, S.F. Hunter, C. Huffman, N. Agashivala, L. Schofield, K. McCague, L.M. Barbato(Vienna, Franklin, Tampa, East Hanover, US)Influence of the mode of walk on walking speed in multiple sclerosis: are you walking comfortably?R. Phan-Ba, G. Delrue, S. Pierard, E. Lommers, P. Calay, M. Vandroogenbroeck, V. Delvaux(Liège, BE)Improvement in physical disability with fingolimod: post-hoc analyses of FREEDOMS and TRANSFORMSN. Bergvall, N. Sfikas, P. Chin, D. Tomic, G. Cutter (Basel, CH; East Hanover, US; Birmingham,US)Motor sequence learning in relapsing-remitting multiple sclerosis (MS) patientsN. Zahiri, I. Abdollahi, A.M. Arab, S.M. Nabavi (Tehran, IR)Cognitive impairment in relapsing-remitting multiple sclerosis patientsA. Altinkaya, E. Ozcan, D. Kuscu, E. Kurt, A. Bingöl, D. Kirbas, B. Topcular (Istanbul, TR)A rare case of cerebroretinal vasculopathy caused by a novel Trex 1 mutationE. Schuh, P. Lohse, T. Kümpfel (Munich, Singen, DE)
  8. 8. 11:30 - 12:30 / POSTER SESSION 2 : MIGRAINE AND PAIN / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREAImpact of chronic pain on the quality of life of patients with multiple sclerosisC. Voiticovschi-Iosob, I. Moldovanu (Chisinau, MD)Long term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis previously treated with interferon beta-1a or disease modifyingtherapies: a post-hoc analysis of the TRANSFORMS 4.5 year extension studyX. Montalban, F. Barkhof, G. Comi, H.-P. Hartung, L. Kappos, B. Khatri, J. Pelletier, E.Kornyeyeva, S. Ritter, P. von Rosenstiel, J. Cohen (Barcelona, ES; Amsterdam, NL; Milan, IT;Düsseldorf, DE; Basel, CH; Milw aukee, US; Marseille, FR; East Hanover, US; Cleveland, US)The relationship between dehydroepiandrosterone and cortisol with fatigue and depression in multiple sclerosisS. Rashidfard, M. Moghadasi, A. Moeini, A. Rahimi, M. Edalatmanesh (Fars, Shiraz, IR)MRI timings and their impact on new T2 lesions’ ability to predict treatment failure in multiple sclerosis (MS)C. Tur, À. Rovira, J. Rio, M. Tintore, J. Sastre-Garriga, C. Auger, J. Castillo, Á. Vidal-Jordana, I.Galan, M.J. Arevalo, R. Mitjana, E. Anglada, G. Arrambide, C. Nos, M. Comabella, X. Montalban(Barcelona, ES)Individualized dosing in the treatment of relapsing-remitting multiple sclerosis (RRMS) using S1P receptor-modulating therapies: a simulation studyF. Mercier (Wintzenheim, FR)Prognostic factors for the early development of clinically definite multiple sclerosis in patients with clinically isolated syndromesV. Martinelli, G. Dalla Costa, G. Di Maggio, B. Colombo, D. Dalla Libera, L. Leocani, R. Furlan, M.Filippi, G. Comi (Milan, IT)Impact of expanded disability status scale (EDSS) on oral health in multiple sclerosis patients: a preliminary studyS. Canbaz Kabay, H. Hatipoglu, M. Gungor Hatipoglu, H. Ozden (Kutahya, Eskisehir, TR)Treatment experience, burden and unmet needs (TRIBUNE) in multiple sclerosis (MS): Turkish dataR. Karabudak, K. Karampampa, A. Gustavsson (Ankara, TR; Stockholm, SE)Intrathecal combined methotrexate and dexametasone therapy in progressive multiple sclerosisM. Volpini, C. Monaldini, M. Stumpo, S. Guttmann (Cailungo, SM)Long term follow-up of autologous stem cell transplantation in multiple sclerosis patientsM. Radaelli, L. Moiola, R. Greco, V. Martinelli, F. Sangalli, P. Rossi, L. Ferrè, M. Comola, P.Vezzulli, J. Peccatori, F. Ciceri, G. Comi (Milan, IT)Lymphocyte counts and infection risk among relapsing-remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II)E. Havrdova, D.L. Arnold, J.A. Cohen, A.J. Coles, C. Confavreux, E.J. Fox, H.-P. Hartung, K.WSelmaj, H.L. Weiner, T. Miller, C.L. Tw yman, S.L. Lake, D.H Margolin, M.A. Panzara, D.A.S.Compston for the CARE-MS II Investigators
  9. 9. 13:30 - 13:45 / ORAL SESSION 13 : MULTIPLE SCLEROSIS II: PATHOLOGY AND PATHOGENESIS / ROOM A13:45 - 14:00 / ORAL SESSION 13 : MULTIPLE SCLEROSIS II: PATHOLOGY AND PATHOGENESIS / ROOM A14:00 - 14:15 / ORAL SESSION 13 : MULTIPLE SCLEROSIS II: PATHOLOGY AND PATHOGENESIS / ROOM A14:15 - 14:30 / ORAL SESSION 13 : MULTIPLE SCLEROSIS II: PATHOLOGY AND PATHOGENESIS / ROOM A14:30 - 14:45 / ORAL SESSION 13 : MULTIPLE SCLEROSIS II: PATHOLOGY AND PATHOGENESIS / ROOM A15:30 - 15:45 / ORAL SESSION 18 : MULTIPLE SCLEROSIS III: OTHER / ROOM A15:45 - 16:00 / ORAL SESSION 18 : MULTIPLE SCLEROSIS III: OTHER / ROOM A16:00 - 16:15 / ORAL SESSION 18 : MULTIPLE SCLEROSIS III: OTHER / ROOM A16:15 - 16:30 / ORAL SESSION 18 : MULTIPLE SCLEROSIS III: OTHER / ROOM A16:30 - 16:45 / ORAL SESSION 18 : MULTIPLE SCLEROSIS III: OTHER / ROOM A16:45 - 17:00 / ORAL SESSION 21 : NEUROREHABILITATION / ROOM F16:45 - 17:00 / ORAL SESSION 18 : MULTIPLE SCLEROSIS III: OTHER / ROOM ACharacterization of individual IgM oligoclonal band antibodies from the cerebrospinal fluid (CSF) of multiple sclerosis patients to identify their antigensE. Beltrán, B. Obermeier, F. Coret, M. Simó-Castelló, F.C. Pérez-Miralles, R. Hohlfeld, B.Casanova, K. Dornmair (Munich, DE; Valencia, ES)Aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disordersJ.S. Tzartos, C. Stergiou, K. Kilidireas, P. Zisimopoulou, T. Thomaidis, S. Tzartos (Athens, GR)Construction of an antibody phage display library from B-cells infiltrating brain tissue of people with progressive multiple sclerosisC. Maggiore, G. Giovannoni, J. Martin, A. Nissim (London, GB)Semaphorin 7A and its receptor expression in multiple sclerosis lesionsE. Martínez-Sáez, C. Costa, A. Gutiérrez, A. Ortega-Aznar, S. Ramón y Cajal, X. Montalban, C.Espejo (Barcelona, ES)Cerebrospinal fluid (CSF) transferrin levels are reduced in patients with early multiple sclerosisM. Khalil, B. Riedlbauer, C. Langkammer, C. Enzinger, S. Ropele, T. Stojakovic, H. Scharnagl, V.Culea, A. Petzold, J.J. Archelos, S. Fuchs, F. Fazekas (Graz, AT; Amsterdam, NL)Abnormalities of the brain functional connectome in paediatric patients with multiple sclerosisM. Filippi, P. Valsasina, M. Absinta, S. Sala, V. Martinelli, A. Ghezzi, P. Veggiotti, A. Falini, G.Comi, M.A. Rocca (Milan, Gallarate, Pavia, IT)R2* as a potential MRI measure for demyelination in MS lesionsC. Langkammer, M. Khalil, C. Enzinger, D. Pinter, S. Fuchs, S. Ropele, F. Fazekas (Graz, AT)Correlation of brain volume loss with multiple sclerosis duration, MRI activity and disability: impact of fingolimod across 3 phase III trialsF. Barkhof, J. Cohen, E.W. Radue, L. Kappos, P. Calabresi, D. Haering, N. Sfikas, P. VonRosenstiel, G. Francis (Amsterdam, NL; Cleveland, US; Basel, CH; Baltimore, US; EastHanover, US)Efficacy and safety of daclizumab high-yield process (DAC HYP) treatment in relapsing-remitting multiple sclerosis: results from the SELECTION extensionstudyG. Giovannoni, R. Gold, K. Selmaj, E. Havrdova, X. Montalban, E.-W. Radue, D. Stefoski, M.McNeill, J. Rana, J. Elkins, G. ONeill (London, GB; Bochum, DE; Lodz, PL; Prague, CZ;Barcelona, ES; Basel, CH; Chicago, US; Maidenhead, GB; Cambridge, US)Effect of BG-12 (dimethyl fumarate) in newly diagnosed patients with relapsing-remitting multiple sclerosis from the DEFINE and CONFIRM studiesR. Gold, G. Giovannoni, J.T. Phillips, R.J. Fox, A. Zhang, L. Meltzer, N.C. Kurukulasuriya(Bochum, DE; London, GB; Dallas, Cleveland, Weston, US)Modifications of functional connectivity of the anterior cingulum correlate with medium-term effects of cognitive rehabilitation in patients with multiplesclerosisL. Parisi, M.A. Rocca, M. Copetti, P. Valsasina, F. Mattioli, R. Capra, G. Comi, M. Filippi (Milan,San Giovanni Rotondo, Brescia, IT)
  10. 10. 17:30 - 18:30 / POSTER SESSION 3 : CLINICAL NEUROPHYSIOLOGY II / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREAThe "Sapere Migliora" information aid for newly-diagnosed multiple sclerosis patients: developing and testing phases following the MRC frameworkA. Giordano, A. Lugaresi, V. Martinelli, F. Granella, P. Confalonieri, M. Trojano, M. MessmerUccelli, C. Borreani, A. Solari on behalf of the SIMS projectTongue somatosensory evoked potentials: evaluation of the afferent trigeminal pathway in patients with early multiple sclerosisM. Krbot Skoric, T. Gabelic, I. Adamec, M. Habek (Zagreb, HR)Impaired deficit recognition in multiple sclerosisE. Reich, E. Arias, C. Torres, E. Halac, M. Kerszberg, M. Carlino (Caba, AR)Risk-associated behaviour in multiple sclerosis: a case control studyC.H Haw kes, D. Boniface (London, GB)Study of magnetisztion transfer MRI in clinically isolated syndromes (CIS)C. Oreja-Guevara, A. Royo, S. Noval, J. Alvarez-Linera (Madrid, ES)Phenotype of neuromyelitis optica in the Czech RepublicP. Zbornikova, P. Nytrova, E. Havrdova, M. Tyblova, J. Lizrova Preiningerova, I. Kovarova, V.Kral, E. Krasulova, M. Vaneckova, D. Horakova (Prague, Usti, CZ)Development of a clinical practice guideline on the managment of multiple sclerosis using the GRADE methodological approachS. Otero-Romero, M.D. Estrada, J. Sastre-Garriga, M. Tintoré, A. Saiz, L.L. Ramió-Torrentà, D.Benítez, M. Espallargues, X. Montalban (Barcelona, Girona, ES)Rio score and modified Rio score validation in an Italian cohort of relapsing-remitting multiple sclerosis patientsA. Nuara, M. Romeo, V. Martinelli, M. Rodegher, S. Maida, E. Perego, G. Comi (Milan, IT)Multiple sclerosis and extra central nervous system malignanciesI. Moreira, A. Martins Silva, E. Santos (Porto, PT)Movement disorders in two multiple sclerosis centres in VenezuelaA. Soto, O Molina, M. Camacaro, I. Soto, M. Gallardo, R. León (Caracas, Maracaibo, Valencia,VE)Frequency of HLA DRB1 gene alleles in patients with multiple sclerosis and the importance of disease course in a Lithuanian populationR. Balnyte, D Rastenyte, A. Vaitkus, I. Urbonaviciute, A. Vitkauskiene, E. Skrodeniene (Kaunas,LT)
  11. 11. 17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : CLINICAL NEUROPHYSIOLOGY II / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : CLINICAL NEUROPHYSIOLOGY II / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : CLINICAL NEUROPHYSIOLOGY II / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : CLINICAL NEUROPHYSIOLOGY II / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREAUse of optical coherence tomography in multiple sclerosis patientsZ. Vladimirova, S. Cherninkova (Sofia, BG)Birth outcomes in fathers with multiple sclerosisE. Lu, F. Zhu, Y. Zhao, M. van der Kop, A. Synnes, L. Dahlgren, A.D. Sadovnick, A.Traboulsee, H. Tremlett (Vancouver, CA)Investigation of central motor pathways in multiple sclerosis with transcranial magnetic stimulationK. Oikonomidi, V. Kimiskidis, S. Papagiannopoulos, M. Karagianni, O. Argiropoulou, E.Koutsouraki, N. Vlaikidis (Thessaloniki, GR)Lifetime hazard of patients with multiple sclerosis according to the database of the Department of Neurology at the University of Szeged between 1993 and2013V. Zsiros, D. Sandi, J. Fuvesi, Z.T. Kincses, Z. Fricska-Nagy, M. Karacsony, H. Huszka, G.Lencses, L. Vecsei, K. Bencsik (Szeged, HU)Cognitive decline emerges beneath a critical threshold of total brain volume in patients with multiple sclerosis: support for the brain reserve hypothesisJ.F. Sumow ski, M.A. Rocca, V.M. Leavitt, G. Riccitelli, G. Comi, J. DeLuca, M. Filippi (WestOrange, US; Milan, IT)Sensitivity of optical coherence tomography and visual evoked potentials in multiple sclerosisG. Di Maggio, B. Mariangela, R. Santangelo, L. Ferrari, S. Guerrieri, S. Medaglini, M. Rodegher,B. Colombo, L. Moiola, U. Del Carro, V. Martinelli, G. Comi, L. Leocani (Milan, IT)Event-related P300 potentials, cognitive impairment and brain atrophy in multiple sclerosis (MS)N. Tevzadze (Tbilisi, GE)The evolution of visual evoked potentials (VEP) parameters in the course of multiple sclerosis (MS)B. Zakrzew ska-Pniew ska, M. Nojszew ska, B. Jakubiak-Mazur, Z. Lew andow ski (Warsaw ,PL)Rasch and traditional validation of the COSM-R, a questionnaire on satisfaction with communication of multiple sclerosis diagnosisA. Solari, M. Grzeda, A. Giordano, A. Simone, L. Vignatelli, K. Mattarozzi, R. DAlessandro, L.Tesio on behalf of the Agorà, GERONIMUS, SIMS-Trial and SIMS-Practice groupsRegional analysis of grey matter damage in African-Americans with multiple sclerosisM. Petracca, R. Teodorescu, J. How ard, L. Fleysher, N. Oesingmann, I. Katz-Sand, J. Herbert,P. Carrieri, M. Inglese (Naples, IT; New York, US)Female sexual dysfunction and sex hormone level during menstrual cycle in multiple sclerosis patientsS. Shahdaei, S. Rastyar, M. Moghadasi, F. Alipour, M. Norouzpour, M.A. Edalatmanesh (Fars,Shiraz, IR)Long-term health-related quality of life in Hungarian patients with multiple sclerosisJ. Füvesi, R. Januska, K. Bencsik, G. Lencsés, Z. Fricska-Nagy, E. Losonczi, C. Rajda, É.
  12. 12. 17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREATUESDAY, JUNE 11, 201309:00 - 09:30 / SYMPOSIUM : PERSONALISED TREATMENT IN MULTIPLE SCLEROSIS / PLENARY HALL09:30 - 10:00 / SYMPOSIUM : PERSONALISED TREATMENT IN MULTIPLE SCLEROSIS / PLENARY HALL10:00 - 10:30 / SYMPOSIUM : PERSONALISED TREATMENT IN MULTIPLE SCLEROSIS / PLENARY HALL10:30 - 11:00 / SYMPOSIUM : PERSONALISED TREATMENT IN MULTIPLE SCLEROSIS / PLENARY HALL11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREALangane, M. Török, L. Vécsei (Szeged, HU)Which test is most suitable to assess cognitive impairment in multiple sclerosis? Comparison of neuropsychological standard tests and the paradigm ofvisual searchK.S. Utz, T.M.A. Hankeln, A. Waschbisch, D.-H. Lee, R.A. Linker, T. Schenk (Erlangen, DE)The relationship between fatigue and severity of disability in multiple sclerosisM. Heidari, M. Akbarfahimi, S.M. Nabavi (Tehran, IR)Does exercise improve cognitive function in multiple sclerosis? Report of a pilot studyB. Sangelaji, S.M. Nabavi (Tehran, IR)Unmet needs of people with severe multiple sclerosis and their carers: qualitative data to construct a home palliative care programmeC. Borreani, E. Bianchi, S. Cilia, M. Giuntoli, E. Pietrolongo, I. Rossi, M.G. Grasso, F. Patti, L.Lopes, A. Lugaresi, P. Confalonieri, P. Morino, L. Palmisano, G. Martino, M. Ponzio, R. Amadeo,P. Zaratin, M.A. Battaglia, A. Giordano, A. Solari on behalf of the PeNSAMI projectCerebrospinal fluid (CSF) free light chains: diagnostic and predictive relevance in multiple sclerosis and clinically isolated syndromeM. Senel, J. Brettschneider, H. Tumani (Ulm, DE)Lower functional connectivity in the default network of memory-impaired patients with multiple sclerosis (MS)V.M. Leavitt, J. Paxton, J.F. Sumow ski (West Orange, US)EfficacyG. Comi (Milan, IT)SafetyA. Siva (Istanbul, TR)Towards personalized medicine in Multiple SclerosisP. Soelberg Sorensen (Copenhagen, DK)Shared decision-making and patient-centred careA. Solari (Milan, IT)Oligoadenylate synthetase 1 gene polymorphism and disease activity of multiple sclerosisW. Fadel, E. El-seidy, K. Rashed, H. Mourad (Tanta, EG)
  13. 13. 11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : NEURO-EPIDEMIOLOGY / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : NEURO-EPIDEMIOLOGY / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREAGenetic associations and clinical course of familial multiple sclerosis in Novosibirsk region of RussiaD. Korobko, N. Malkova, E. Sokolova, M. Filipenko (Novosibirsk, RU)Surface expansion of the hippocampal dentate gyrus in multiple sclerosis: in vivo evidence of neurogenesis?P. Preziosa, G. Longoni, M.A. Rocca, E. Pagani, G. Riccitelli, B. Colombo, M. Rodegher, A. Falini,G. Comi, M. Filippi (Milan, IT)Dynamic patterns of grey and white matter atrophy in patients with clinically isolated syndrome suggestive of multiple sclerosis one year from first clinicalepisodeP. Preziosa, M.A. Rocca, S. Mesaros, E. Pagani, D. Damjanovic, T. Stosic-Opincal, J. Drulovic,M. Filippi (Milan, IT; Belgrade, RS)Influence of depression and fatigue on the regional distribution of brain damage in patients with multiple sclerosisG. Riccitelli, M.A. Rocca, C. Gobbi, E. Pagani, P. Preziosa, V. Martinelli, M. Radaelli, G. Comi, M.Filippi (Milan, IT)The effect of immunomodulating therapies on cGMP concentration in brain cortex of experimental autoimmune encephalomyelitis (EAE)N. Lubina-Dabrow ska, G. Sulkow ski, B. Dabrow ska-Bouta, J. Langfort, A. Stepien, M.Chalimoniuk (Warsaw , PL)Microstructural damage to normal appearing white matter (NAWM) and grey matter (GM) but not to cortical lesions contributes to cognitive impairment inmultiple sclerosis: a diffusion tensor MRI studyM. Filippi, E. Pagani, M.E. Morelli, P. Preziosa, M. Copetti, D. Dalla Libera, V. Martinelli, A. Falini,G. Comi, M.A. Rocca (Milan, San Giovanni Rotondo, IT)Plasma adipocytokines and oral contraceptive use in patients with relapsing-remitting multiple sclerosisC. Capela, A. Sena, C. Nóbrega, A. Sousa, R. Roque, M. Cascais, V. Ferret-Sena, R. Pedrosa(Lisbon, PT)Demographic and clinical characteristics of multiple sclerosis patients in the Upper Silesia region of Poland: preliminary studyM. Adamczyk-Sow a, K. Pierzchala, K. Kubicka, P. Sow a (Zabrze, PL)The prevalence of multiple sclerosis and dietary factors: an ecological study using data from the Food and Agriculture OrganisationK. Lauer (Griesheim, DE)The importance of neutralizing antibodies in relapsing-remitting multiple sclerosisC. Baetu, R.E. Martin, I. Buraga (Bucharest, RO)Natalizumab treatment influences peroxisome proliferator-activated receptors (PPARs) and CD36 receptor mRNA expression in patients with multiplesclerosisA. Sousa, V. Ferret-Sena, I. Cavaleiro, A. Maia e Silva, G. Chinetti-Gbaguidi, B. Derudas, B.Staels, J. Vale, M. Veloso, R. Pedrosa, A. Sena (Lisbon, PT; Lille, FR)
  14. 14. 11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : NEURO-EPIDEMIOLOGY / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : NEURO-EPIDEMIOLOGY / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA11:30 - 12:30 / POSTER SESSION 4 : CHILD NEUROLOGY / POSTER AREAPET study of pathogenesis of cognitive impairment in varying degrees of disability in patients with different types of multiple sclerosisG. Shkilnyuk, A. Ilves, G. Katayeva, L. Prakhova, I. Stolyarov (Saint Petersburg, RU)FTY720 is neuroprotective after toxin-induced central nervous system demyelinationA. Slow ik, T. Schmidt, S. Amor, C. Beyer, M. Kipp (Aachen, DE)Analysis of the integrity of the pyramidal tract (PT) in response to lesions in patients with clinically isolated syndrome (CIS)M. Paw litzki, J. Heidel, J. Kaufmann, E. Stadler, M. Sailer (Magdeburg, DE)Who gets admitted to neurology beds? Experience from a tertiary referral centre in EgyptS. El Taw il, T. Emara, N. Kasim, A. Abdelhak (Cairo, EG)Loss of brain tissue accompanied by decrease of processing speed: the main determinant of cognitive performance in patients with multiple sclerosis?E. Stadler, P. Bublak, R. Deppe, J. Feiss, M. Fischer, F. Hoffmann, A. Kunkel, M. Schw ab, K.Voigt, U. Zettl, W. Köhler, M. Sailer (Magdeburg, Jena, Halle, Teupitz, Wermsdorf, Rostock, DE)Predictors of disability extremes in patients with multiple sclerosis treated with interferon-beta using the Swedish multiple sclerosis registryK. Fink, A. Glaser, A. Fogdell-Hahn, J. Hillert (Stockholm, SE)Comparing objective measures of neurodegeneration in multiple sclerosis (MS)V. Fernandez, M.J. Postigo, P. Urbaneja, A. Leon, A. Alonso, M. Guerrero, O. Fernandez(Málaga, ES)Prognostic value of cerebrospinal fluid (CSF) cytology in clinically isolated syndrome for subsequent progression to multiple sclerosisY. Motuzova, F. Granieri, P. Valentino, A. Sala, G. Amadore, A. Bertolotto (Minsk, BY;Orbassano, IT)Serum levels of apoptosis-related proteins in multiple sclerosis (MS) patientsM. Moreno, M. Sáenz-Cuesta, J. Castilló, E. Cantó, R. Nurtdinov, C. Tur, X. Montalban, M.Comabella (Barcelona, ES)No evidence for single nucleotide polymorphisms in the MMP9 gene conferring multiple sclerosis (MS) susceptibilityC. Wolf, S. Nischw itz, D. Buck, UK. Zettl, P. Rieckmann, B. Hemmer, M. Ising, S. Lucae, T.Bettecken, B. Mueller-Myhsok, F. Weber (Munich, Rostock, Bamberg, DE)Neurological comorbidities in children and adolescents with migraine headacheA. Potic, D. Momcilovic-Kostadinovic, D. Stupar, J. Vujovic, G. Tricomi (Belgrade, RS; Bologna,IT)
  15. 15. 11:30 - 12:30 / POSTER SESSION 4 : CHILD NEUROLOGY / POSTER AREA16:15 - 17:00 / TEACHING COURSE 17 : MEASURING HETEROGENEITY IN MULTIPLE SCLEROSIS: THE MRI PERSPECTIVE / ROOM ADemyelinating clinically isolated syndrome mimicking acute brainstem ischaemia in an eight year old child with patent foramen ovaleL. Ferrè, L. Moiola, M. Radaelli, V. Barcella, F. Sangalli, C. Baldoli, F. Triulzi, V. Martinelli, G.Comi (Milan, IT)Imaging the spinal cord in multiple sclerosis and clinical correlationsO. Ciccarelli (London, GB)

×